Kiniksa Pharmaceuticals International Plc’s recently made public that its Officer Tessari Eben acquired Company’s shares for reported $0.27 million on Feb 10 ’25. In the deal valued at $19.57 per share,14,000 shares were bought.
Then, Tessari Eben sold 14,000 shares, generating $255,413 in total proceeds. Upon selling the shares at $18.24, the CHIEF OPERATING OFFICER now owns 88,975 shares.
Before that, Tessari Eben bought 14,000 shares. Kiniksa Pharmaceuticals International Plc shares valued at $255,390 were divested by the Officer at a price of $18.24 per share.
Jefferies initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on September 13, 2024; the price target was $40. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early May with a ‘”an Overweight”‘ rating. BofA Securities also remained covering KNSA and reiterated its “Buy” recommendation on June 29, 2020. BofA/Merrill started covering the stock on April 01, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock jump 0.51% to $19.70. Over the last five days, the stock has gained 5.12%. Kiniksa Pharmaceuticals International Plc shares have fallen nearly -0.40% since the year began. Nevertheless, the stocks have risen 3.58% over the past one year. While a 52-week high of $28.15 was reached on 01/28/25, a 52-week low of $16.56 was recorded on 01/13/25. SMA at 50 days reached $20.10, while 200 days put it at $22.05.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 18.63, which if violated will result in even more drops to 17.56. On the upside, there is a resistance level at 20.26. A further resistance level may holdings at 20.82. The Relative Strength Index (RSI) on the 14-day chart is 49.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 43.17%. Stochastics %K at 48.44% indicates the stock is a holding.
How much short interest is there in Kiniksa Pharmaceuticals International Plc?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc stocks on 2025-01-31, dropping by -1.46 million shares to a total of 1.93 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 3.39 million shares. There was a decline of -75.65%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 11, 2019 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $26 price target.
